Short answer
Lucid Diagnostics Inc. (LUCD) filed an 8-K current report with the SEC on April 24, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Reg FD item contains only standard non-incorporation disclaimer language.
Lucid Diagnostics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD item contains only standard non-incorporation disclaimer language
- No substantive business, financial, or market-moving disclosure identified
Item 8.01 · Other Events
- $18.0 million gross equity offering from 18,000,000 shares at $1.00 each
- Approximately $16.8 million net proceeds after underwriting discounts and offering expenses
- Proceeds earmarked for working capital and general corporate purposes
- Equity issuance creates shareholder dilution and strengthens near-term liquidity
- Offering closed April 24, 2026, with Canaccord Genuity and BTIG as joint bookrunners
Item EX-99.1 · Exhibit EX-99.1
- $18M gross proceeds from 18M shares priced at $1.00 each, strengthening near-term liquidity
- $15M institutional investment anchored the offering, with support from a large existing shareholder
- Net proceeds earmarked for working capital and general corporate purposes
- Equity issuance creates dilution for existing shareholders and may pressure the stock price
- Capital raise supports Lucid’s commercial operations and funding needs as a PAVmed subsidiary
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lucid Diagnostics Inc. 8-K filings
Get the next LUCD 8-K as it lands
Follow LUCD for push alerts, or ask the research agent what this filing means.